2025 Presenting Companies

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

AstronauTx is developing a portfolio of small molecule therapeutics which will restore and enhance the healthy physiology of the brain by boosting the natural physiological mechanisms which support healthy brain function. This novel and orthogonal approach to treating neurodegenerative disease will both improve the symptoms of the disease and prevent the vicious cycle of worsening pathology.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with neurological conditions. With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases.

Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. We are a privately held company financed by a strong syndicate of investors consisting of Novo Holdings, Sofinnova Partners, M Ventures, SR One, Orbimed, EQT, Johnson & Johnson Innovation – JJDC, Inc. and Kurma Partners.We have one ultimate goal: To deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients. Asceneuron has two small molecule O-GlcNAcase inhibitors (ASN51 and ASN90) that leverage a central protein modification system to slow protein aggregation. Both ASN51 and ASN90 have completed 3 Phase 1 studies, demonstrating high O-GlcNAcase inhibition in the brain.

Luma Vision, a groundbreaking start-up based in Dublin and Munich, aims to transform healthcare with its innovative navigation and imaging platform for cardiology. LUMA’s mission is to revolutionize cardiac procedures by creating cutting edge hardware, software, and data science solutions that address global clinical needs in arrhythmias and structural heart. Their flagship product, VERAFEYE™, is an innovative, 4D navigation and imaging platform with catheter, advanced digital imaging and deep learning techniques. The platform aims to deliver unprecedented personalised data delivered at the point of therapy. LUMA Vision has raised €37M in funding and secured an additional €10M in prestigious grants.

 Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA.

Nobi is the smartest lamp in the world, designed for fall detection, fall prevention and even fall prediction. With its sophisticated AI-model and cutting-edge technology, Nobi offers safety and peace of mind while blending seamlessly into each interior.

Nobi empowers elderly to live at home longer. In care facilities, it supports busy caregivers by taking over repetitive, administrative tasks and summarizing important parameters in one easy form.

The smart lamp also brings caregivers peace of mind by keeping an eye out 24/7, assuring them that immediate help can be provided when a fall occurs.

We believe DDR-targeting therapies can play a significant role in the treatment of malignant disease, and we aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients.

VarmX has built an advanced pipeline in bleeding and coagulation disorders, leveraging the cutting-edge research of Professor Pieter Reitsma, a globally recognized authority. VarmX’s lead product, VMX-C001, is a novel, modified recombinant factor X specifically engineered to address critical unmet needs in bleeding management of patients on Factor Xa inhibitors (DOACs). VMX-C001 is in late stage clinical development for the prevention of bleeding in patients undergoing urgent surgery and for the treatment of severe spontaneous bleeding. VarmX is backed by a consortium of renowned investors—EQT Life Sciences, Sound Bioventures, EIC, Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter

Nua Surgical is a maternal health company which has received global recognition for their patented invention; the SteriCISION C-section Retractor. The device aims to improve access and visualisation during Caesarean Delivery thus reducing risk factors that lead to surgical complications.

ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). For more information, visit ONWD.com.

ReimaginingAntibody Drug Conjugates:
Tubulis generates uniquely matched protein-drug conjugates
through the combination of novel proprietary technologies
and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of antibodydrug
conjugates (ADCs) by increasing design flexibility while
overcoming constraints of toxicity, efficacy and indication.
Tubulis will build new conjugates to fill its pipeline and will
collaborate with partners to usher in a new ADC era and deliver
better outcomes for patients.

Ariceum Therapeutics develops targeted radiopharmaceuticals in cancer.Our lead clinical radiopharmaceutical is 177Lu/225Ac-satoreotide (SS0110), an antagonist of the SSTR2 receptor. Satoreotide is developed as a ‘theranostic’ pair for diagnosis and targeted radionuclide treatment of SCLC and MCC.
Our second product ATT001 is a 123Iodine-radiolabeled PARP inhibitor in Phase 1 in recurrent glioblastoma, an indication of high unmet medical need.
Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumours.
In partnership with UCB Pharma, we develop macrocyclic peptides against novel targets to develop first-in-class radiopharmaceuticals expanding our pipeline beyond the lead assets.

Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. We do this by targeting biologically validated pathways - including Transforming Growth Factor β and Hepatocyte Growth Factor - and by applying specialized capabilities in organ-restricted small molecules and high affinity antibodies. With a differentiated clinical pipeline across several fibrotic disorders, end-to-end research and development capabilities, a proven BD track-record and a strong investor base, Agomab is building a leading biopharma company.